← All trials
NCT07064122
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 3, 2025
- Primary completion
- Oct 20, 2028
- Completion date
- Oct 20, 2028
- First posted
- Jul 14, 2025
- Last posted
- Nov 17, 2025
- Enrollment
- 72
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
- ParexelCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.